Eisbach Bio Secures CPRIT Grant to Advance Novel Cancer Therapeutic Eisbach Bio received a $4.75M award from the Cancer Prevention and Research Institute of Texas for clinical development of its novel allosteric inhibitor.

Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors The first patient has been dosed in Eisbach Bio’s Phase 1/2 MATCH clinical trial at MD Anderson assessing the ALC1 inhibitor EIS-12656 in solid tumors.

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors